glp-1 agonists muscle loss GDF8 and activin A blockade protects against GLP-1–induced while enhancing fat loss in obese male mice and non-human primates Using glp-1 receptor agonists for

Retatrutide administered once weekly subcutaneously for 12 weeks resulted in a dose-dependent placebo-adjusted weight loss of up to 8.96 kg in the highest dose group and a placebo-adjusted HbA1c reduction of up to 1.6% in a phase II trial in individuals with T2DM [125]

Older adults over age sixty-five may experience different side effect profiles and weight loss patterns than younger users

Additionally, evaluating how these therapies interact with current antidiabetic treatments and determining their suitability for combination therapies may further enhance their clinical value

Risks related to anesthesia, aspiration, and retained gastric contents Reports of retained gastric contents and aspiration risk have increased with the widespread use of GLP-1RAs

Publication bias was assessed using Eggers test

Dose adjustments, side effect management strategies, adding complementary medications, or modifying your titration schedule may resolve problems without requiring a complete reversal